Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1320587
European Journal of Endocrinology, Vol 132, Issue 5, 587-593
Copyright © 1995 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Preziati, D.
Right arrow Articles by Beck-Peccoz, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Preziati, D.
Right arrow Articles by Beck-Peccoz, P.

Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a

Daniela Preziati, Luigi La Rosa, Giovanni Covini, Rosaria Marcelli, Stefania Rescalli, Luca Persani, Ersilio Del Ninno, Pier Luigi Meroni, Massimo Colombo and Paolo Beck-Peccoz

Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni PL, Colombo M, Beck-Peccoz P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995;132:587–93. ISSN 0804–4643

The occurrence of thyroid abnormalities and the appearance of organ- and non-organ-specific autoantibodies during long-term recombinant interferon alpha-2a (IFN-{alpha}) therapy were studied in 86 and 51 consecutive outpatients with hepatitis C and B virus-related chronic active hepatitis (CAH-HCV and CAH-HBV), respectively. Most patients had longstanding community-acquired hepatitis. At baseline, 9.3% of CAH-HCV and 3.9% of CAH-HBV patients showed clinical and/or biochemical signs of thyroid dysfunction. The remaining patients were euthyroid, although anti-thyroid autoantibodies were found in 33/78 (42.3%) of CAH-HCV and in 5/49 (10.2%) of CAH-HBV patients. During IFN-{alpha} treatment, increased anti-thyroid autoantibody levels were seen in 40% of CAH-HCV initially negative patients, while they became detectable in no more than 10% of CAH-HBV patients. Interferon-{alpha}-induced hypo- or hyperthyroidism was recorded in 12 of 35 CAH-HCV patients treated for 12 months (34.3%). Only one CAH-HBV patient developed hyperthyroidism. High titers of anti-nuclear auto-antibodies (ANA) were recorded at enrolment in 5/36 (13.8%) of CAH-HCV and in 3/16 (18.7%) of CAH-HBV patients. Only one CAH-HCV patient displayed anti-parietal cell antibodies (PCA). After IFN-{alpha} treatment, ANA were found in 10/28 (35.7%) and PCA in 2/28 (7.1%) of CAH-HCV patients, while an additional CAH-HBV patient developed PCA, but not ANA. However, no signs of systemic autoimmune disease were recorded. In conclusion, more than half of the patients with chronic active hepatitis C, but only one-tenth of those with hepatitis B, displayed thyroid- and/or non-organ-specific autoantibodies prior to or during treatment with IFN-{alpha}. As most of the antibody-positive patients developed permanent thyroid disorders during IFN-{alpha} therapy, the risk of development of organ-specific autoimmunity should be assessed carefully and incorporated in the cost/effectiveness analysis in patients with longstanding hepatitis who are candidates for IFN-{alpha} treatment.

Paolo Beck-Peccoz, Institute of Endocrine Sciences, Ospedale Maggiore IRCCS, Padiglione Granelli, Via F. Sforza 35, 20122-Milano, Italy




This article has been cited by other articles:


Home page
 Mult SclerHome page
R. Hoftberger, F. Garzuly, H.P. Dienes, J. Grubits, B. Rohonyi, G. Fischer, Z. Hanzely, H. Lassmann, and H. Budka
Fulminant central nervous system demyelination associated with interferon-{alpha} therapy and hepatitis C virus infection
Multiple Sclerosis, November 1, 2007; 13(9): 1100 - 1106.
[Abstract] [PDF]

Home page
 Eur J EndocrinolHome page
M. Rotondi, R. Minelli, F. Magri, P. Leporati, P. Romagnani, M. C. Baroni, R. Delsignore, M. Serio, and L. Chiovato
Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-{alpha} therapy for hepatitis C virus-related hepatitis
Eur. J. Endocrinol., April 1, 2007; 156(4): 409 - 414.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. Devendra, J. Jasinski, E. Melanitou, M. Nakayama, M. Li, B. Hensley, J. Paronen, H. Moriyama, D. Miao, G. S. Eisenbarth, et al.
Interferon-{alpha} as a Mediator of Polyinosinic:Polycytidylic Acid-Induced Type 1 Diabetes
Diabetes, September 1, 2005; 54(9): 2549 - 2556.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
E. J. Bini and S. Mehandru
Incidence of Thyroid Dysfunction During Interferon Alfa-2b and Ribavirin Therapy in Men With Chronic Hepatitis C: A Prospective Cohort Study
Arch Intern Med, November 22, 2004; 164(21): 2371 - 2376.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Carella, G. Mazziotti, G. Amato, L. E. Braverman, and E. Roti
Interferon-{alpha}-Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3656 - 3661.
[Full Text] [PDF]

Home page
 QJMHome page
A. Antonelli, C. Ferri, P. Fallahi, D. Giuggioli, C. Nesti, G. Longombardo, P. Fadda, A. Pampana, M. Maccheroni, and E. Ferrannini
Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia
QJM, August 1, 2004; 97(8): 499 - 506.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
W. B. Chan, C. C. Chow, and C. S. Cockram
Interferon alpha treatment and endocrine disease
J R Soc Med, October 1, 2003; 96(10): 481 - 485.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Ramos-Casals, O. Trejo, M. Garcia-Carrasco, and J. Font
Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection
Rheumatology, July 1, 2003; 42(7): 818 - 828.
[Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
I Kotter, M Zierhut, A K Eckstein, R Vonthein, T Ness, I Gunaydin, B Grimbacher, S Blaschke, W Meyer-Riemann, H H Peter, et al.
Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis
Br. J. Ophthalmol., April 1, 2003; 87(4): 423 - 431.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. Durelli, B. Ferrero, A. Oggero, E. Verdun, A. Ghezzi, E. Montanari, and M. Zaffaroni
Liver and thyroid function and autoimmunity during interferon-{beta}1b treatment for MS
Neurology, October 23, 2001; 57(8): 1363 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
E. Dieperink, M. Willenbring, and S. B. Ho
Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review
Am J Psychiatry, June 1, 2000; 157(6): 867 - 876.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
M. T. Bardella, R. Marino, and P. L. Meroni
Celiac Disease during Interferon Treatment
Ann Intern Med, July 20, 1999; 131(2): 157 - 158.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Luft, K. C. Pang, E. Thomas, P. Hertzog, D. N. J. Hart, J. Trapani, and J. Cebon
Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells
J. Immunol., August 15, 1998; 161(4): 1947 - 1953.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
L. Fernandez-Soto, A. Gonzalez, F. Escobar-Jimenez, R. Vazquez, E. Ocete, N. Olea, and J. Salmeron
Increased Risk of Autoimmune Thyroid Disease in Hepatitis C vs Hepatitis B Before, During, and After Discontinuing Interferon Therapy
Arch Intern Med, July 13, 1998; 158(13): 1445 - 1448.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 European Society of Endocrinology.